{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:07:33Z","timestamp":1791191253226,"version":"4.1.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,5,15]]},"DOI":"10.1097\/tp.0b013e3181d21e7f","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T05:40:39Z","timestamp":1268890839000},"page":"1095-1102","source":"Crossref","is-referenced-by-count":218,"title":["Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation"],"prefix":"10.1097","volume":"89","author":[{"given":"Ashley A.","family":"Vo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieko","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Kahwaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hung","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Reinsmoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Villicana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley C.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210129","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1056\/NEJM198502283120905","article-title":"The quality of life of patients with end-stage renal disease.","volume":"312","author":"Evans","year":"1985","journal-title":"N Engl J Med"},{"key":"R2-7-20210129","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1001\/jama.1993.03510110079036","article-title":"Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients.","volume":"270","author":"Port","year":"1993","journal-title":"JAMA"},{"key":"R3-7-20210129","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/00007890-199210000-00018","article-title":"The quality of life in renal transplantation\u2014A prospective study.","volume":"54","author":"Russell","year":"1992","journal-title":"Transplantation"},{"key":"R6-7-20210129","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1056\/NEJMoa0707894","article-title":"Rituximab and intravenous immune globulin for desensitization during renal transplantation.","volume":"359","author":"Vo","year":"2008","journal-title":"N Engl J Med"},{"key":"R7-7-20210129","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/TP.0b013e3181856f98","article-title":"Acceptable donor-specific antibody levels allowing for successful deceased and living donor kidney transplantation after desensitization therapy.","volume":"86","author":"Reinsmoen","year":"2008","journal-title":"Transplantation"},{"key":"R8-7-20210129","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1097\/01.ASN.0000145878.92906.9F","article-title":"Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end stage renal disease: Report of the NIH IG02 trial.","volume":"15","author":"Jordan","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R9-7-20210129","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1046\/j.1600-6135.2003.00273.x","article-title":"Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: Contraindication vs. risk.","volume":"3","author":"Gebel","year":"2003","journal-title":"Am J Transplant"},{"key":"R10-7-20210129","first-page":"258","article-title":"HLA antibody and donor reactivity define patients at risk for rejection or graft loss.","volume":"2","author":"Kerman","year":"2002","journal-title":"Am J Transplant"},{"key":"R11-7-20210129","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.humimm.2004.06.001","article-title":"Pronase treatment facilitates alloantibody flow cytometric and cytotoxic crossmatching in the presence of rituximab.","volume":"65","author":"Bearden","year":"2004","journal-title":"Hum Immunol"},{"key":"R12-7-20210129","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/01.TP.0000165110.78397.93","article-title":"Co-infection of polyomavirus-BK and cytomegalovirus in renal transplant recipients.","volume":"80","author":"Toyoda","year":"2005","journal-title":"Transplantation"},{"key":"R13-7-20210129","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1111\/j.1600-6143.2006.01472.x","article-title":"Effects of induction therapy protocols on transplant outcomes in crossmatch positive renal allograft recipients desensitized with IVIG.","volume":"6","author":"Vo","year":"2006","journal-title":"Am J Transplant"},{"key":"R14-7-20210129","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1600-6143.2007.02017.x","article-title":"Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab.","volume":"8","author":"Vo","year":"2008","journal-title":"Am J Transplant"},{"key":"R15-7-20210129","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1600-6143.2006.01688.x","article-title":"Banff '05 Meeting Report: Differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (\u2018CAN\u2032).","volume":"7","author":"Solez","year":"2007","journal-title":"Am J Transplant"},{"key":"R16-7-20210129","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1399-3046.2005.00363.x","article-title":"Current approaches to treatment of antibody-mediated rejection.","volume":"9","author":"Jordan","year":"2005","journal-title":"Pediatr Transplant"},{"key":"R17-7-20210129","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/00007890-199402270-00014","article-title":"Intravenous immunoglobulin suppression of HLA alloantibody in highly sensitized transplant candidates and transplantation with a histoincompatible organ.","volume":"57","author":"Tyan","year":"1994","journal-title":"Transplantation"},{"key":"R18-7-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/TP.0b013e3181a9e89a","article-title":"Intravenous immunoglobulin a natural regulator of immunity and inflammation.","volume":"88","author":"Jordan","year":"2009","journal-title":"Transplantation"},{"key":"R20-7-20210129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1600-6143.2005.01214.x","article-title":"Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients.","volume":"6","author":"Jordan","year":"2006","journal-title":"Am J Transplant"},{"key":"R21-7-20210129","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2215\/CJN.01651105","article-title":"Presensitization: The problem and its management.","volume":"1","author":"Jordan","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R22-7-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1432-2277.2004.tb00376.x","article-title":"Intravenous immunoglobulins and transplantation for patients with anti-HLA antibodies.","volume":"17","author":"Glotz","year":"2004","journal-title":"Transpl Int"},{"key":"R23-7-20210129","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/00007890-200011270-00023","article-title":"A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants.","volume":"70","author":"Schweitzer","year":"2000","journal-title":"Transplantation"},{"key":"R24-7-20210129","first-page":"213","article-title":"Renal transplantation at the Johns Hopkins Comprehensive Transplant Center.","volume":"199","author":"Montgomery","year":"2003","journal-title":"Clin Transpl"},{"key":"R25-7-20210129","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1097\/00007890-199809270-00017","article-title":"Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action.","volume":"66","author":"Jordan","year":"1998","journal-title":"Transplantation"},{"key":"R26-7-20210129","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00007890-200101150-00009","article-title":"A randomized and prospective study comparing treatment with high-dose intravenous immunoglobulin with monoclonal antibodies for rescue of kidney grafts with steroid-resistant rejection.","volume":"71","author":"Casadei","year":"2001","journal-title":"Transplantation"},{"key":"R27-7-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00007890-200108150-00010","article-title":"Reversal of steroid and anti-lymphocyte antibody-resistant rejection using intravenous immunoglobulin (IVIG) in renal transplant recipients.","volume":"72","author":"Luke","year":"2001","journal-title":"Transplantation"},{"key":"R28-7-20210129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"R29-7-20210129","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell targeted therapy with rituximab in rheumatoid arthritis.","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"R30-7-20210129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/ncpneph0133","article-title":"Drug insight: Rituximab in renal disease in transplantation.","volume":"4","author":"Salama","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"R31-7-20210129","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nri1838","article-title":"B-cell targeting in rheumatoid arthritis and other autoimmune diseases.","author":"Edwards","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"R32-7-20210129","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood-2007-12-129262","article-title":"Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab.","volume":"112","author":"Stasi","year":"2008","journal-title":"Blood"},{"key":"R33-7-20210129","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: Potential effects on T cells.","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol"},{"key":"R34-7-20210129","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/01.TP.0000112934.12622.2B","article-title":"Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: Safety, pharmacodynamics, and pharmacokinetics.","volume":"77","author":"Vieira","year":"2004","journal-title":"Transplantation"},{"key":"R35-7-20210129","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.tp.0000261113.30757.d1","article-title":"Rituximab therapy for acute humoral rejection after kidney transplantation.","volume":"83","author":"Faguer","year":"2007","journal-title":"Transplantation"},{"key":"R36-7-20210129","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"R37-7-20210129","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/TP.0b013e3181880b35","article-title":"Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.","volume":"86","author":"Billing","year":"2008","journal-title":"Transplantation"},{"key":"R38-7-20210129","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev.immunol.26.021607.090232","article-title":"Anti-inflammatory actions of intravenous immunoglobulin.","volume":"26","author":"Nimmerjahn","year":"2008","journal-title":"Annu Rev Immunol"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/TP.0b013e3181d21e7f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:20:34Z","timestamp":1786040434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-201005150-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,15]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3181d21e7f","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.3456961.3152059","asserted-by":"object"}]},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2010,5,15]]}}}